Key Takeaways After losing and regaining weight for years, Signos’s founder built the first FDA-cleared glucose monitor for weight management.
Fouladgar-Mercer’s company has grown 10x in six months by pairing CGM technology with AI to help people understand their metabolism.
Sharam Fouladgar-Mercer always struggled with his weight. Even as a Division I hockey player at Princeton, he noticed his teammates could eat 5,000 calories a day without gaining a pound while he struggled on far less.
Same diet, same exercise, completely different results. The math never added up.
He spent years yo-yoing back and forth — losing the weight, gaining it back, losing it again. The cycle was exhausting and, more than anything, confusing.
It wasn’t until 2018, when a diabetic friend showed him a continuous glucose monitor strapped to his arm, that something clicked.
“Why are we waiting until people have a chronic care condition before enabling them to learn from their own body’s natural signals?”
That question became Signos — the first FDA-cleared glucose monitoring platform for weight management. The company has grown more than 10x in the last six months, positioning itself as a tool for anyone serious about understanding their own metabolism — including the tens of thousands coming off GLP-1 medications every day who need a new plan.
Related: This Founder Is Taking a Bite Out of the $50 Billion GLP-1 Market By Going Natural
Proving it on himself
... continue reading